Alfasigma USA, Inc. v. First Databank, Inc.

Background

Alfasigma develops, manufactures, sells, and distributes medical foods that, according to its allegations, must be used under a physician’s supervision. First Databank publishes and sells MedKnowledge, a pharmaceutical information database used by insurance companies, pharmacy benefit managers, doctors, pharmacies, wholesalers, and others to make decisions about products.

The dispute concerned MedKnowledge’s classification codes for Alfasigma’s products. First Databank changed the meaning of the “F” classification and assigned Alfasigma’s medical foods to the “O” classification, later assigning them to the “Q” classification. Alfasigma alleged that customers understood “O” to mean an over-the-counter product and that payors therefore stopped reimbursing the products, causing fewer prescriptions, lower inventory, and lost sales.

The second amended complaint asserted Lanham Act claims for false advertising and false description of source, along with a claim for contributory false advertising. Alfasigma’s amended theory focused on statements that the information in MedKnowledge came from the Food and Drug Administration and manufacturers, rather than directly challenging the database’s product classifications. First Databank moved to dismiss the second amended complaint under Federal Rule of Civil Procedure 12(b)(6), which allows dismissal when a complaint does not plausibly state a legally valid claim.

Statutory Standing

First Databank argued that Alfasigma lacked statutory standing, meaning that the Lanham Act did not authorize Alfasigma to bring these claims. The court rejected the argument that a plaintiff must be a direct competitor to fall within the statute’s protected interests. It held that Alfasigma’s allegations of lost sales were enough to satisfy the Lanham Act’s zone-of-interests requirement, which asks whether the plaintiff’s alleged injury is the type the statute protects.

The court then considered proximate cause, which asks whether the alleged injury has a sufficiently direct connection to the defendant’s conduct. The court concluded that Alfasigma had not plausibly alleged this requirement. The Editorial Highlights at issue did not mention Alfasigma’s products and did not directly disparage them. Instead, Alfasigma’s claimed loss depended on a series of later decisions by insurance companies, pharmacy benefit managers, doctors, pharmacies, wholesalers, and consumers.

The court found no close, nearly automatic relationship between First Databank’s statements and Alfasigma’s lost sales. It also noted that First Databank did not decide which products would be prescribed, reimbursed, purchased, or stocked, and that Alfasigma identified other sources of information and independent reasons that could have affected those decisions. Determining how much of Alfasigma’s loss resulted from First Databank’s statements would therefore require speculative or uncertain inquiries.

Disposition

The court held that Alfasigma had not plausibly pleaded proximate cause and therefore lacked statutory standing to bring its Lanham Act claims. Judge Haywood S. Gilliam, Jr. granted First Databank’s motion to dismiss. The court found that amendment would be futile because Alfasigma had already had multiple opportunities to amend and would need to contradict its earlier allegations to establish proximate cause. The court granted the motion without leave to amend, directed the clerk to enter judgment for First Databank, and ordered the case closed.